CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 80 enrolled
Drug / intervention
methylprednisolone therapy +1 moredrug
Likely dose
methylprednisolone therapy 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04244591
NCT04244591Phase 3Completed
CompareCT.gov

Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial

Peking Union Medical College Hospital·interventional·Posted Jan 28, 2020·Updated Jun 16, 2020

In Brief

A Phase 3 clinical trial evaluating methylprednisolone therapy and Standard care for COVID-19 Infections. Completed, enrolled 80 participants across 1 site.

Detailed Summary

In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for COVID-19 patents with Severe acute respiratory failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Infections
CountriesChina
CollaboratorsZhongda Hospital, Zhongnan Hospital, Renmin Hospital of Wuhan University

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 28, 2020
Enrollment StartJan 26, 2020
Primary CompletionApr 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.4 years ago

Interventions

methylprednisolone therapydrug

Methylprednisolone 40 mg q12h for 5 days

Standard careother

Standard care